In a recent study assessing the impact of RNI among node-positive HER2-positive breast cancer patients who were enrolled in the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation (ALTTO) trial [9], there was no significant association between RNI and DFS in patients receiving optimal anti-HER2 targeted therapies [10]. Here, ERBB2 is linked to breast carcinoma.